First biologic therapy for young children with severe eczema

Child with eczema

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial.

Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal antibody for any skin disease in patients aged six months to six years.

The study, published in The Lancet showed that the drug reduced skin itch and pain within two weeks, as well as improving patients’ sleep, and the quality of life of patients and their parents.

The therapy is already licensed in the UK for adults and children aged six to 18, and was approved by the FDA in June 2022 for use in younger children.

Principle Investigator for Manchester and Academic Paediatrician Peter Arkwright, has been investigating the use of dupilumab in children with severe eczema at Royal Manchester Children Hospital’s Clinical Research Facility (CRF) since August 2015.

Arkwright said: “Young children and infants who have moderate-to-severe eczema have a substantially reduced quality of life. It’s also incredibly stressful for their families, particularly as children’s sleep is so disturbed. 

“These pivotal trial results strongly support the global approval of dupilumab in infants and children with eczema. It will revolutionise clinical practice worldwide.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free